Gilead, AstraZeneca and Pfizer likely to win the COVID-19 treatment development race

More than 1 200 therapeutics and vaccines have entered the research and development (R&D) pipeline since January 2020 and this number grows every week says data and analytics company GlobalData.

According to GlobalData’s Clinical and Commercial Analyser tool, which rates the most promising and high-profile assets on a range of clinical and commercial attributes, remdesivir is the clear winner when it comes to therapeutics based on its clinical efficacy and the strength of its developer, Gilead.

Vaccine Image by Arek Socha from Pixabay
The need to address the COVID-19 pandemic is unequivocally being answered by the pharma and biotech industry

Remdesivir

Michael Breen, PhD, director of Infectious Diseases and Ophthalmology at GlobalData, comments: “The need to address the COVID-19 pandemic is unequivocally being answered by the pharma and biotech industry. A broad-spectrum antiviral, remdesivir is one of a select few agents to show benefit for severe COVID-19 patients owing to its clear mechanism of action, becoming the standard of care in many countries. On the vaccines front, it is a more complicated story.

“GlobalData’s analysis shows that AstraZeneca and Pfizer/BioNtech are in the lead vaccine-wise, but this finding is based on preliminary data and the story could rapidly change once data on disease prevention become available. While registered, Russia’s Sputnik V appears to be weaker than other assets due to the dearth of available data.”

Other promising agents

Given the number of players already involved, determining where each lies in the race to develop COVID-19 therapeutics and vaccines is extraordinarily complex and constantly evolving. For example, understanding where chloroquine/hydroxychloroquine fits has been complicated by the volume of often conflicting and low quality data.

Breen notes: “GlobalData’s analyser shows that the likelihood of chloroquine/hydroxychloroquine being successful is low, due to the poor quality of data supporting their use in combination with more rigorous studies suggesting a lack of utility.

“There are a number of other agents that are extremely promising. For vaccines, we would have to call out Moderna’s mRNA-1273 vaccine, which entered the clinic at a blistering pace and may be the first to show positive Phase III data in the US. For therapeutics, Lilly’s monoclonal antibody LY-CoV555 is a highly promising therapeutic, while antivirals such as favipiravir may be highly beneficial in moderate patients.

“Additionally, immunomodulators such as tocilizumab or baricitinib may be able to show benefit for quelling hyper-inflammation when used in combination with an antiviral such as remdesivir. There is no shortage of candidates to help with COVID-19, but what is lacking right now is data on their efficacy.”



Latest


25 Sep 2020
New dates for MAGHREB PHARMA

Easyfairs Northeral, the organiser of MAGHREB PHARMA Expo has announced new dates for its annual international tradeshow for the pharmaceutical…

New dates for MAGHREB PHARMA

Easyfairs Northeral, the organiser of MAGHREB PHARMA Expo has announced new dates for its annual international tradeshow for the pharmaceutical industry in North Africa. In this context, the Algerian Pharmaceutical Industry Minister, Lotfi Benbahmed, announced end of August in Algiers that Algeria plans to export the equivalent of $ 5…

25 Sep 2020
Are you the next generation of brave healthcare professionals?

Season 2 of ‘Sponsors of Brave’ is now open for nominations.  The 2020 Sponsors of Brave campaign – a partnership…

Are you the next generation of brave healthcare professionals?

Season 2 of ‘Sponsors of Brave’ is now open for nominations.  The 2020 Sponsors of Brave campaign – a partnership between Adcock Ingram OTC and News24 – aims to celebrate the unsung heroes and brave professionals in healthcare. In particular, season 2 recognises that pursuing a career in healthcare during…

25 Sep 2020
How data sciences will help you get optimum value from your factory floor

Industry 4.0 and IIoT have been buzz words for several years and these concepts are actually implemented on more and more machines.  …

How data sciences will help you get optimum value from your factory floor

Industry 4.0 and IIoT have been buzz words for several years and these concepts are actually implemented on more and more machines.   A huge amount of data becomes available: machine data, data of the production process and data regarding the manufactured product. Big Data has entered the factory floor.  Data pipeline   Data…

23 Sep 2020
Merck expands its ADC manufacturing capabilities

Merck has announced a € 59 million expansion of its HPAPI and ADC manufacturing capabilities and capacity at its facility…

Merck expands its ADC manufacturing capabilities

Merck has announced a € 59 million expansion of its HPAPI and ADC manufacturing capabilities and capacity at its facility near Madison, Wisconsin, USA. This investment will allow large-scale manufacturing of increasingly potent compounds for therapies that have the potential to treat cancer. Completion is expected by mid-2022 and should…


Top stories


23 Apr 2020
Are you South Africa’s best female entrepreneur?

Entries are now open for the Santam Women of the Future Awards 2020 in association with Fairlady and True Love.…

Are you South Africa’s best female entrepreneur?

Entries are now open for the Santam Women of the Future Awards 2020 in association with Fairlady and True Love. Santam, Fairlady and, for the first time this year, Truelove Magazine, have partnered up in the search to find the best female entrepreneurs in the country. Best women entrepreneurs If…

30 Nov 2017
Rooibos could reduce risk of “Type 3” diabetes – a precursor to Alzheimer’s

Researchers at Warren Alpert Medical School at Brown University in the US found a link between a relatively new form…

Rooibos could reduce risk of “Type 3” diabetes – a precursor to Alzheimer’s

Researchers at Warren Alpert Medical School at Brown University in the US found a link between a relatively new form of diabetes, known as “type 3” diabetes and Alzheimer’s disease.

25 Jun 2020
How to ensure business agility in a pandemic

BY: Neil Birch, CEO at Novus Holdings Business agility is the capability of a business to respond quickly to a…

How to ensure business agility in a pandemic

BY: Neil Birch, CEO at Novus Holdings Business agility is the capability of a business to respond quickly to a changing environment, whether it be internal or external. Qualities of agile businesses include being adaptive, flexible and creative in your response to change without losing momentum (remaining productive) or vision.…

01 May 2020
Fibertex manufactures critical components for COVID-19 PPE

Fibertex SA, part of the global Fibertex Nonwovens group, has developed versatile high-performance components for protective facemasks and respirators. “Fibertex,…

Fibertex manufactures critical components for COVID-19 PPE

Fibertex SA, part of the global Fibertex Nonwovens group, has developed versatile high-performance components for protective facemasks and respirators. “Fibertex, which continuously invests in technological advancements to meet requirements in diverse industries – has increased production capacity of materials so desperately needed during the global COVID-19 pandemic,” explains Rosa Naidoo,…


Visit the official COVID-19 government website to stay informed: sacoronavirus.co.za